Clinical Trial Detail

NCT ID NCT02197572
Title Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Millennium Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

Therapies

Sapanisertib

Age Groups: adult

No variant requirements are available.